One of the most exciting themes for those looking to capitalize on the changing global cannabis industry is the rollout of Canada's Marihuana for Medical Purposes Regulations (MMPR). Health Canada, which oversees Canada’s national medical marijuana program, has issued licenses to 23 companies, several of which trade or are soon expected to trade publicly. PharmaCan Capital Corp., which is based in Toronto, has made investments in 5 of Canada’s current Licensed Producers. The company, which just went public on the TSX Venture Exchange under the symbol MJN, is led by Paul Rosen, its President and CEO.
Alan: Thank you, Paul, for taking the time to tell us about PharmaCan Capital and congratulations on your recent listing. Before we discuss your company, can you tell us about your background?
Paul: I was born and raised in Toronto, where I reside with my family. I earned a degree in economics, followed by a law degree from the University of Toronto. I practiced criminal and constitutional law in Canada for a number of years, and I remain a member of the Law Society of Upper Canada. I have also played a leadership role in the development number of companies and became the President and CEO of PharmaCan in March 2013.
Alan: Why did you decide to enter the MMJ industry?
Paul: I entered the medical marijuana industry as it provides a unique combination of opportunity, entrepreneurial spirit and the ability to deliver a plant with incredible therapeutic properties. While I have had previous success starting and building companies, PharmaCan provided the extra opportunity to be a stakeholder in the development of an important new industry that will improve the quality of life for so many Canadians. I could not be more passionate, excited and committed.
Alan: Can you describe the efforts ...